Comments
Lincoln Pharmaceuticals Limited on Thursday posted standalone net profit of ₹15 crore for the first quarter ended June 2020, as against ₹12 crore in the corresponding quarter a year ago, showing a nearly 25-per cent jump on year-on-year basis.
Company’s standalone revenues from operations stood at ₹101 crore, up from ₹95 crore in the same quarter last year.
EBITDA for the quarter ended June 2020 was reported at ₹22.42 crore as compared to ₹19.04 crore in the corresponding period last year.
On consolidated basis, the company posted net profit of ₹15 crore as against ₹13 crore in the corresponding quarter last year. Consolidated revenues from operations stood at ₹104 crore for the quarter under review as against ₹97 crore in the same period last year.
Mahendra Patel, MD, Lincoln Pharmaceuticals, said, “We are pleased to announce that Lincoln Pharma has become a zero net-debt company by paying all its outstanding debt. Despite a challenging economic and business environment due to Covid-19, the company has delivered a robust financial performance quarter over quarter maintaining healthy growth in revenue, profitability and expects to continue the growth momentum in the coming years.”
Lincoln Pharma shares traded at ₹237.10, down by about 0.2 per cent on BSE Thursday.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.